A number of other analysts have also issued reports on HLS. Raymond James dropped their price objective on shares of HLS Therapeutics from C$10.00 to C$9.00 and set a market perform rating on the stock in a research note on Friday, July 28th. Stifel Nicolaus lowered shares of HLS Therapeutics from a buy rating to a hold rating and dropped their price target for the stock from C$12.25 to C$5.00 in a research note on Friday.
HLS Therapeutics Trading Down 6.4 %
HLS Therapeutics (TSE:HLS – Get Free Report) last posted its quarterly earnings data on Thursday, August 10th. The company reported C($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.17) by C($0.22). HLS Therapeutics had a negative return on equity of 20.38% and a negative net margin of 41.67%. The business had revenue of C$22.05 million for the quarter, compared to analyst estimates of C$21.17 million. During the same quarter last year, the business earned ($0.36) EPS. Equities analysts forecast that HLS Therapeutics will post -0.12 EPS for the current fiscal year.
HLS Therapeutics Company Profile
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.
- Five stocks we like better than HLS Therapeutics
- How to Invest in Communication Stocks
- MarketBeat Week in Review – 11/6 – 11/10
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Data giants MongoDB and Snowflake just got upgraded
- Best Stocks Under $5.00
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.